Resibufogenin Suppresses Triple-Negative Breast Cancer Angiogenesis by Blocking VEGFR2-Mediated Signaling Pathway

• Main Authors: Ting Yang (Author), Yi-Xin Jiang (Author), Ye Wu (Author), Dong Lu (Author), Rui Huang (Author), Long-Ling Wang (Author), Shi-Qi Wang (Author), Ying-Yun Guan (Author), Hong Zhang (Author), Xin Luan (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Resibufogenin (RBF), an active compound from Bufo bufonis, has been used for the treatment of multiple malignant cancers, including pancreatic cancer, colorectal cancer, and breast cancer. However, whether RBF could exert its antitumor effect by inhibiting angiogenesis remains unknown. Here, we aime...